ADC Therapeutics (ADCT) Receivables - Other (2021 - 2023)

ADC Therapeutics (ADCT) has reported Receivables - Other for 3 consecutive years, with $2.1 million the latest figure, recorded in Q3 2023.

• Quarterly Receivables - Other rose 25.25% year-over-year to $2.1 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $2.1 million (up 25.25% YoY) and the FY2022 annual result came in at $805000.0, up 2.03% from the prior year.
• Receivables - Other grew to $2.1 million in Q3 2023 per ADCT's latest filing, from $1.5 million in the prior quarter.
• Over the last five years, Receivables - Other for ADCT reached as high as $2.1 million in Q3 2023 and fell as low as $789000.0 in Q4 2021.
• A 3-year average of $1.2 million and a median of $1.0 million in 2022 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2022 — Receivables - Other climbed 2.03% — and 2023, when it soared 69.18%.
• Year by year, Receivables - Other stood at $789000.0 in 2021, then rose by 2.03% to $805000.0 in 2022, then soared by 163.73% to $2.1 million in 2023.
• According to Business Quant data, Receivables - Other over the past three periods registered $2.1 million, $1.5 million, and $1.1 million for Q3 2023, Q2 2023, and Q1 2023 respectively.